Care for Pregnant and Postpartum People with Substance Use Disorder Patient Safety Bundle

Core Data Collection Plan
**Measurement Statement:** For the purposes of quality improvement measurement and standardized data collection and reporting, AIM includes the following substances as part of its definition of SUD: opioids, amphetamines/stimulants, sedatives, and cocaine. A list of ICD-10 codes is at the end of this document.

## State Surveillance

<table>
<thead>
<tr>
<th>Metric</th>
<th>Name</th>
<th>Description</th>
<th>Notes</th>
</tr>
</thead>
</table>
| SS1    | Substance use disorders among pregnant and postpartum people | **A. Denominator:** All people during their birth hospitalization, excluding those with ectopic pregnancies and miscarriages  
**Numerator:** Among the denominator, those with any a diagnosis of **substance use disorder**  
**B. Denominator:** All people during their birth hospitalization, excluding those with ectopic pregnancies and miscarriages  
**Numerator:** Among the denominator, those with a diagnosis of **opioid use disorder** | Disaggregate by race/ethnicity |
| SS2    | Severe Maternal Morbidity (SMM) (including transfusion codes) among people with SUD | **A. Denominator:** All people during their birth hospitalization, excluding those with ectopic pregnancies and miscarriages, with **substance use disorder**  
**Numerator:** Among the denominator, those with any SMM code  
**B. Denominator:** All people during their birth hospitalization, excluding those with ectopic pregnancies and miscarriages, with **opioid use disorder**  
**Numerator:** Among the denominator, those with any SMM code | Disaggregate by race/ethnicity |
<table>
<thead>
<tr>
<th>Metric</th>
<th>Name</th>
<th>Description</th>
<th>Notes</th>
</tr>
</thead>
</table>
| SS3    | Severe Maternal Morbidity (SMM) (excluding transfusion codes) among people with SUD | **A. Denominator:** All people during their birth hospitalization, excluding those with ectopic pregnancies and miscarriages, with _substance use disorder_  
**Numerator:** Among the denominator, all those with any non-transfusion SMM code  
**B. Denominator:** All people during their birth hospitalization, excluding those with ectopic pregnancies and miscarriages, with _opioid use disorder_  
**Numerator:** Among the denominator, those with any non-transfusion SMM code | Disaggregate by race/ethnicity |
| SS4    | Proportion of pregnancy associated deaths due to overdose           | **Denominator:** Total pregnancy-associated deaths  
**Numerator:** Pregnancy-associated deaths due to overdose                                                                                                                                                     | Disaggregate by race/ethnicity  |
## Outcome Measures

<table>
<thead>
<tr>
<th>Metric</th>
<th>Name</th>
<th>Description</th>
<th>Notes</th>
</tr>
</thead>
</table>
| O1     | Percent of newborns exposed to substances in utero who were discharged to either birth parent | **Report N/D**  
**Denominator:** Newborns exposed to substances in utero  
**Numerator:** Among the denominator, those who were discharged to either birth parent | Disaggregate by race/ethnicity  
This outcome may also be interpreted as a balancing measure |
| O2     | Percent of pregnant and postpartum people with OUD who **received or were referred to** medication for opioid use disorder (MOUD) | **Report N/D**  
**Denominator:** Pregnant and postpartum people with a diagnosis of opioid use disorder  
**Numerator:** Among the denominator, those with documentation of having received or been referred to MOUD prior to discharge from their birth hospitalization  
*Refer to P2 for complementary measure.* | Disaggregate by race/ethnicity  
**Include in the numerator:**  
• Those who received MOUD at any point during their pregnancy, regardless of current use  
• Those who did not receive MOUD during pregnancy but were referred to MOUD prior to discharge from birth hospitalization |
<table>
<thead>
<tr>
<th>Metric</th>
<th>Name</th>
<th>Description</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>O3</td>
<td>Percent of pregnant and postpartum people with SUD who <strong>received or were referred to</strong> recovery treatment services</td>
<td><strong>Report N/D</strong>&lt;br&gt;&lt;br&gt;<strong>Denominator:</strong> Pregnant and postpartum people with a diagnosis of <strong>substance use disorder, including opioid use disorder</strong>&lt;br&gt;&lt;br&gt;<strong>Numerator:</strong> Among the denominator, those with documentation of having <strong>received or been referred to</strong> recovery treatment services prior to discharge from their birth hospitalization&lt;br&gt;&lt;br&gt;Refer to P4 for complementary measure.</td>
<td>Disaggregate by race/ethnicity&lt;br&gt;&lt;br&gt;<strong>Include in the numerator:</strong>&lt;br&gt;• Those who received recovery treatment services at any point during their pregnancy, regardless of current utilization&lt;br&gt;• Those who did not receive recovery treatment services during pregnancy but were referred to them prior to discharge from birth hospitalization&lt;br&gt;&lt;br&gt;<strong>Recovery treatment services include:</strong>&lt;br&gt;• Residential treatment or inpatient recovery programs&lt;br&gt;• Outpatient treatment&lt;br&gt;• Behavioral health counseling&lt;br&gt;• Peer support counseling, such as a 12-step program&lt;br&gt;• Methadone treatment program</td>
</tr>
<tr>
<td>O4</td>
<td>Percent of pregnant and postpartum people with SUD who <strong>received or were prescribed</strong> Naloxone prior to delivery discharge</td>
<td><strong>Report N/D</strong>&lt;br&gt;&lt;br&gt;<strong>Denominator:</strong> Pregnant and postpartum people with a diagnosis of <strong>substance use disorder</strong>&lt;br&gt;&lt;br&gt;<strong>Numerator:</strong> Among the denominator, those with documentation of having <strong>received or been prescribed</strong> Naloxone prior to discharge from their birth hospitalization&lt;br&gt;&lt;br&gt;Refer to P4 for complementary measure.</td>
<td>Disaggregate by race/ethnicity</td>
</tr>
</tbody>
</table>
## Process Measures

<table>
<thead>
<tr>
<th>Metric</th>
<th>Name</th>
<th>Description</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>P1</td>
<td>Percent of pregnant and postpartum people screened for SUDs</td>
<td><strong>Sample patient charts or report for all patients; report N/D</strong>  <strong>Denominator:</strong> Pregnant and postpartum people during their birth hospitalization  <strong>Numerator:</strong> Among the denominator, those with documentation of having been screened for substance use disorder using a <strong>validated verbal screening tool</strong> during their birth hospitalization</td>
<td>Disaggregate by race/ethnicity</td>
</tr>
</tbody>
</table>
| P2 | Percent of pregnant and postpartum people with OUD who were **counseled** on medication for opioid use disorder (MOUD) | **Report N/D**  **Denominator:** Pregnant and postpartum people with a diagnosis of opioid use disorder during their birth hospitalization  **Numerator:** Among the denominator, those with documentation of counseling for MOUD prenatally or during their birth hospitalization  
*Refer to O2 for complementary measure* | Disaggregate by race/ethnicity |
| P3 | Percent of pregnant and postpartum people with SUD who were **counseled** on recovery treatment services | **Report N/D**  **Denominator:** Pregnant and postpartum people with a diagnosis of substance use disorder, including opioid use disorder during their birth hospitalization  **Numerator:** Among the denominator, those with documentation of counseling for recovery treatment services prenatally or during their birth hospitalization  
*Refer to O3 for complementary measure* | Disaggregate by race/ethnicity  
**Recovery treatment services include:**  
• Residential treatment or inpatient recovery programs  
• Outpatient treatment  
• Behavioral health counseling  
• Peer support counseling, such as a 12-step program  
• Methadone treatment program |
<table>
<thead>
<tr>
<th>Metric</th>
<th>Name</th>
<th>Description</th>
<th>Notes</th>
</tr>
</thead>
</table>
| P4     | Percent of pregnant and postpartum people with SUD who received Naloxone counseling | **Report N/D**  
**Denominator:** Pregnant and postpartum people with a diagnosis of *substance use disorder* during their birth hospitalization  
**Numerator:** Among the denominator, those with documentation of *counseling* for Naloxone prenatally or during their birth admission  
*Refer to O4 for complementary measure* | Disaggregate by race/ethnicity |
| P5     | Provider and Nursing Education – *Substance Use Disorders* | **Report proportion completed**  
*(estimated in 10% increments – round up)*  
At the end of this reporting period, what cumulative proportion of OB providers and nurses (including L&D and PP) has received within the last 2 years an education program on *care for pregnant and postpartum people with substance use disorders*? | |
| P6     | Provider and Nursing Education – *Respectful and Equitable Care* | **Report proportion completed**  
*(estimated in 10% increments-round up)*  
At the end of this reporting period, what cumulative proportion of inpatient clinical OB providers and nursing staff has received within the last two years an education program on *respectful and equitable care*? | |
<table>
<thead>
<tr>
<th>Metric</th>
<th>Name</th>
<th>Description</th>
<th>Notes</th>
</tr>
</thead>
</table>
| S1     | Resource Mapping/ Identification of Community Resources | **Report Initial Completion Date**  
Has your hospital created a comprehensive list of community resources, customized to include resources relevant for pregnant and postpartum people, that will be shared with all postpartum inpatient nursing units and outpatient OB sites? | • Resource list should be updated annually.  
• Resource list should include OUD/SUD treatment resources as well as mental health resources and allow for customization based on patient population (e.g. BIPOC) |
| S2     | Patient Event Debriefs                    | **Report Start Date**  
Has your department established a standardized process to conduct debriefs with patients after a severe event? | • Include patient support networks during patient event debriefs, as requested  
• Severe events may include the TJC sentinel event definition, severe maternal morbidity, or fetal death |
| S3     | General Pain Management Guidelines        | **Report Completion Date**  
Has your hospital implemented post-delivery and discharge pain management prescribing guidelines for routine vaginal and cesarean births focused on limiting opioid prescriptions? | |
| S4     | OUD Pain Management Guidelines            | **Report Completion Date**  
Has your hospital implemented specific pain management and opioid prescribing guidelines for patients with a diagnosis of opioid use disorder? | |
| S5     | Validated Verbal Screening Tools and Resources Shared with Prenatal Care Sites | **Report Completion Date**  
Has your hospital shared with all its prenatal care sites validated verbal screening and follow up tools for diagnosis of opioid use and substance use disorders? | Follow up tools include Screening, Brief Intervention and Referral to Treatment (SBIRT) resources. |
# AIM Data SUD Codes List

<table>
<thead>
<tr>
<th>Substance</th>
<th>Definition</th>
</tr>
</thead>
</table>